Treatment for patients with extensive disease (ES-SCLC) includes systemic chemotherapy (cisplatin or carboplatin plus etoposide) combined with immune checkpoint inhibitors (ICIs) targeting the programmed cell death ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) pathway. Here, CD274 is linked to small cell lung carcinoma.